influenza
viru
caus
five
outbreak
wave
human
infect
china
sinc
pose
dual
challeng
public
health
poultri
industri
urgent
need
develop
effect
vaccin
reduc
pandem
potenti
present
studi
evalu
biochem
characterist
immunogen
two
viruslik
particl
vlp
compos
matrix
hemagglutinin
wildtyp
hawt
hemagglutinin
whose
transmembran
domain
replac
subtyp
hatm
vlpswt
vlpstm
could
assembl
releas
supernat
cell
similar
morpholog
characterist
howev
compar
vlpswt
vlpstm
trimer
ha
protein
could
better
resist
thermal
chang
mice
vlpstm
induc
higher
titer
hi
igg
ifnc
provid
better
protect
homolog
heterolog
virus
matter
belong
yangtz
river
delta
pearl
river
delta
challeng
less
weight
loss
higher
surviv
rate
summari
vlpstm
repres
potenti
strategi
develop
vaccin
novel
reassort
avian
influenza
viru
emerg
china
februari
caus
human
infect
februari
laboratori
confirm
human
case
infect
fatal
rate
approxim
caus
unpreced
threat
public
health
poultri
industri
although
humantohuman
transmiss
nt
report
viru
caus
five
epidem
wave
china
evolv
two
main
diversifi
lineag
yangtz
river
delta
yrd
pearl
river
delta
prd
lineag
base
hemagglutinin
ha
gene
virus
yrd
lineag
react
less
well
postinfect
ferret
antiserum
rais
prd
candid
vaccin
indic
remark
differ
antigen
two
lineag
highli
pathogen
hp
viru
belong
prd
lineag
first
report
late
februari
indic
continu
evolut
viru
current
influenza
vaccin
mainli
reli
trivalentquadrival
inactiv
live
attenu
vaccin
embryon
chicken
egg
need
prolifer
influenza
virus
iv
howev
hpaiv
poorli
prolifer
embryo
eggbas
technolog
timeconsum
cumbersom
process
hardli
satisfi
urgent
demand
vaccin
altern
eggbas
technolog
viruslik
particl
vlp
mani
incompar
advantag
special
secur
effect
immun
easi
oper
use
prevent
iv
hepat
e
viru
hev
human
papillomaviru
hpv
human
immunodefici
viru
hiv
sever
acut
respiratori
syndrom
sar
influenza
vaccin
confer
protect
close
relat
strain
frequent
reformul
chang
candid
vaccin
viru
cvv
influenza
antigen
variant
highlight
urgenc
import
vaccin
crossprotect
could
protect
wide
varieti
influenza
subtyp
group
report
recombin
ha
rha
transmembran
domain
tm
subtyp
trimer
protein
tend
stabl
thermal
chang
moreov
mice
vaccin
rhatm
could
increas
crossprotect
interclad
subtyp
studi
intend
explor
whether
vlp
compos
matrix
ha
wildtyp
wt
ha
replac
tm
could
construct
compar
differ
characterist
immunolog
properti
two
vlp
spodoptera
frugiperda
insect
cell
maintain
suspens
serumfre
medium
invitrogen
carlsbad
ca
spinner
flask
speed
rpm
ha
segment
follow
eight
strain
synthes
first
seven
isol
belong
yrd
lineag
last
one
isol
belong
prd
lineag
fig
virus
use
assess
effect
humor
cellular
immun
purifi
describ
previous
furthermor
use
challeng
supplementari
data
associ
articl
found
onlin
version
http
ha
contain
tm
ha
hatm
obtain
overlap
pcr
base
ha
segment
hawt
tm
ha
two
vlp
automat
assembl
hawttm
protein
express
bactobac
express
system
name
vlpswt
vlpstm
briefli
hawthatm
clone
pfastbacdu
vector
invitrogen
carlsbad
ca
recombin
bacmid
transfect
insect
cell
get
recombin
baculovirus
rbv
wt
recombin
baculovirus
rbv
tm
three
passag
rbvswttm
cell
vlpswttm
yield
ml
cell
infect
third
passag
rbvwttm
vlpswttm
harvest
h
postinfect
supernat
purifi
sucros
densiti
gradient
ultracentrifug
purifi
vlpswt
vlpstm
neg
stain
electron
microscopi
jeolltd
japan
observ
cleavabl
precursor
ha
vlp
subunit
determin
escal
concentr
tpcktrypsin
sigma
darmstadt
germani
previous
describ
thermal
resist
purifi
vlpswt
vlpstm
conduct
peltier
gradient
thermal
cycler
waltham
usa
temperatur
min
ha
titer
measur
cool
room
temperatur
seri
twofold
dilut
purifi
vlpswt
vlpstm
pb
prepar
incub
min
chicken
red
blood
cell
rbc
ha
titer
calcul
highest
dilut
factor
produc
posit
read
hi
assay
conduct
previous
describ
brief
receptor
destroy
enzym
rde
seiken
japan
use
treat
mice
serum
h
follow
inactiv
rde
h
ha
unit
eight
inactiv
virus
work
antigen
antibodi
titer
express
log
highest
dilut
give
complet
hemagglutin
inhibit
total
ninetynin
femal
balbc
mice
divid
three
group
n
per
group
receiv
vlpswt
vlpstm
pb
mice
subcutan
immun
twice
twoweek
interv
vlp
contain
lg
ha
formul
freund
adjuv
serum
sampl
taken
two
week
boost
vaccin
serolog
test
total
n
per
group
three
week
boost
twentyseven
mice
group
randomli
divid
three
group
nine
mice
challeng
intranas
mld
respect
three
day
post
challeng
three
mice
sacrif
determin
iv
replic
lung
remain
six
mice
monitor
daili
weight
loss
death
day
infect
mous
lost
bodi
weight
human
euthan
regard
dead
elisa
assay
use
assess
igg
total
antibodi
titer
igg
isotyp
titer
antibodi
titer
serum
immun
mice
eight
purifi
virus
protein
viru
coat
concentr
ngml
llwell
incub
serial
dilut
serum
sampl
detect
previou
describ
abil
splenocyt
secret
ifnc
stimul
differ
virus
evalu
elispot
ezsep
dakew
china
brief
freshli
isol
splenocyt
immun
mice
seed
plate
well
precoat
antimifnc
three
purifi
inactiv
iv
ad
well
concentr
lgml
incub
h
process
number
spot
count
immunospot
elispot
reader
bioread
biosi
germani
viru
titer
lung
perform
plaqu
assay
use
madindarbi
canin
kidney
mdck
cell
describ
previous
detect
limit
assay
titer
pfulung
lung
sampl
titer
less
assign
valu
pfulung
repres
undetect
level
viru
statist
analysi
perform
use
graphpad
prism
unpair
student
ttest
anova
follow
tukey
multipl
comparison
test
use
statist
comparison
statist
analysi
statist
differ
two
group
indic
p
p
p
p
vlp
could
automat
assembl
releas
supernat
cell
ha
gene
iv
previous
report
sucros
densiti
gradient
centrifug
use
purifi
vlpswttm
major
vlpswt
tm
locat
sucros
densiti
furthermor
ha
activ
titer
supernat
vlpswt
vlpstm
purif
vlpswt
vlpstm
exhibit
higher
ha
titer
contain
lg
ha
protein
per
lg
vlp
respect
data
indic
compar
puriti
vlpswt
vlpstm
electron
microscopi
observ
neg
stain
vlpswttm
present
influenza
virion
shape
diamet
rang
nm
show
typic
spike
surfac
viral
particl
except
empti
insid
fig
ha
protein
express
cell
report
form
uncleav
precursor
cleav
perform
proper
function
fusion
host
cell
endosom
membran
low
ph
condit
verifi
cleavag
hawttm
assembl
vlpswttm
purifi
vlpswttm
treat
tpcktrypsin
min
hawttm
vlpswttm
present
approxim
kda
could
cleav
subunit
concentr
cleavag
complet
fig
ha
tpcktrypsin
assay
show
hawt
tm
vlpswttm
activ
correctli
fold
previou
studi
show
recombin
ha
protein
tm
ha
could
increas
content
ha
trimer
enhanc
thermal
stabil
reason
two
cystein
tm
ha
could
bond
disulfidebond
sa
intermonom
ha
investig
whether
vlpstm
disulfidebond
ha
trimer
higher
thermal
resist
vlpswt
purifi
vlpswttm
analyz
nonreduc
western
blot
thermal
resist
analysi
result
display
vlpstm
time
ha
trimer
vlpswt
fig
thermal
resist
stabil
vlpstm
better
vlpswt
fig
especi
ha
titer
vlpstm
reduc
vlpstm
sharpli
decreas
p
investig
differ
immun
respons
vlpswt
vlpstm
mice
subcutan
immun
twice
use
vlpswt
vlpstm
pb
freund
adjuv
respect
two
week
boost
vaccin
blood
spleen
collect
determin
level
humor
cellular
immun
challeng
diverg
virus
mice
vaccin
vlpswt
vlpstm
present
hi
titer
rang
seven
virus
yrd
lineag
indic
vlpswt
vlpstm
could
induc
high
hi
titer
virus
belong
yrd
vlpstm
induc
higher
hi
titer
vlpswt
p
fig
hi
titer
mice
vaccin
vlpstm
averag
hi
titer
vlpswt
less
averag
hi
titer
human
mice
correl
protect
infect
iv
strain
belong
prd
lineag
mice
vaccin
pb
produc
undetect
hi
titer
thu
mice
vaccin
vlpstm
could
develop
higher
hi
titer
vlpswt
diverg
virus
use
studi
vlpstm
group
present
signific
increas
eight
virusspecif
igg
antibodi
level
compar
vlpswt
group
fig
inquir
differ
level
igg
isotyp
antibodi
test
well
vlpstm
elicit
significantli
higher
level
antibodi
vlpswt
p
fig
differ
antibodi
elicit
vlpswt
vlpstm
reach
signific
level
fig
b
well
specif
igg
antibodi
fig
ifnc
vlpstm
group
significantli
higher
vlpswt
group
stimul
virus
fig
level
signific
differ
found
two
group
fig
overal
vlpstm
could
induc
higher
level
hi
antibodi
total
igg
antibodi
isotyp
antibodi
ifnc
secret
vlpswt
determin
level
protect
provid
vlpswt
vlpstm
mice
challeng
lethal
dose
mld
three
week
boost
vaccin
observ
daili
day
monitor
weight
loss
surviv
rate
mice
vaccin
vlpswt
vlpstm
surviv
whole
observ
period
challeng
homolog
heterolog
virus
belong
yrd
lineag
fig
howev
mice
challeng
homolog
viru
show
less
weight
loss
challeng
heterolog
viru
mice
immun
vlpstm
show
less
weight
loss
mice
immun
vlpswt
fig
c
maximum
weight
loss
mice
immun
vlpswt
day
post
infect
compar
vlpstm
day
post
infect
mice
complet
protect
challeng
return
normal
bodi
weight
last
day
observ
fig
mice
immun
vlpswt
show
weight
loss
compar
immun
vlpstm
fig
surviv
rate
product
influenza
virusspecif
cytokin
splenocyt
immun
mice
week
boost
vaccin
spleen
isol
immun
mice
n
splenocyt
stimul
purifi
virus
follow
ifnc
b
elispot
assay
vlpswt
vlpstm
respect
fig
one
mous
immun
vlpswt
lost
bodi
weight
day
post
infect
mice
immun
pb
euthan
weight
loss
surviv
rate
challeng
three
virus
fig
f
result
indic
mice
immun
vlpstm
could
complet
protect
mice
lethal
challeng
homolog
heterolog
virus
furthermor
lung
viral
load
analyz
three
day
challeng
result
show
viru
shed
significantli
reduc
mice
immun
vlpswt
vlpstm
fig
mice
pb
group
highest
lung
viral
titer
notabl
mice
immun
vlpswt
detect
viral
titer
log
pfuml
log
pfuml
gener
vlpstm
could
confer
better
protect
homolog
heterolog
virus
challeng
less
loss
bodi
weight
higher
surviv
rate
lower
viral
load
lung
recent
year
great
quantiti
work
carri
develop
univers
vaccin
safeti
efficaci
protect
vivo
remain
improv
present
work
dedic
enhanc
crossprotect
vlp
increas
trimer
ha
molecul
ha
metast
trimer
surfac
glycoprotein
undergo
extens
conform
rearrang
low
ph
previou
work
team
prove
influenza
viru
ha
subunit
vaccin
could
enhanc
crossprotect
challeng
increas
trimer
ha
protein
moreov
research
confirm
strategi
inactiv
vaccin
influenza
virus
applic
vlp
first
time
result
demonstr
vlp
replac
tm
domain
possess
trimer
ha
protein
provid
better
protect
homolog
heterolog
challeng
strategi
provid
good
idea
allevi
develop
univers
influenza
vaccin
caus
five
epidem
wave
china
wave
divid
mani
clade
continu
evolut
ha
gene
gener
isol
virus
cluster
yrd
prd
lineag
yrd
lineag
includ
zhejiang
jiangsu
shanghai
viru
first
detect
maximum
number
case
document
prd
lineag
refer
guangdong
region
second
largest
number
moreov
hp
variant
virus
caus
human
death
poultri
outbreak
prd
lineag
work
seven
isol
yrd
lineag
one
isol
prd
lineag
use
amino
acid
sequenc
homolog
vlp
form
ha
belong
yrd
lineag
heterolog
virus
use
challeng
belong
yrd
lineag
lowest
homolog
belong
prd
lineag
isol
recent
want
explor
crosslineag
protect
vlp
result
show
vlpstm
confer
complet
protect
homolog
heterogen
strain
hi
titer
wide
use
evalu
influenza
viru
protect
effici
hi
titer
greater
consid
correl
protect
human
influenza
viru
infect
popul
cohort
vaccin
appear
poorli
immunogen
induc
lower
level
hi
antibodi
compar
titer
induc
human
season
influenza
virus
kamal
et
al
point
larg
fraction
antibodi
induc
wiv
nonneutr
vitro
antibodi
direct
ha
head
could
complet
protect
mice
homolog
viral
challeng
despit
low
level
hi
neutral
antibodi
vlp
report
vlpswttm
induc
high
level
igg
hi
antibodi
complet
protect
mice
challeng
homolog
heterolog
virus
belong
yrd
lineag
vlpswttm
elicit
high
igg
antibodi
low
hi
antibodi
vlpswt
vlpstm
respect
belong
prd
lineag
notabl
vlpswttm
could
also
provid
protect
one
mice
immun
vlpswt
euthan
lost
initi
weight
consid
dead
despit
low
hi
titer
coincid
former
conclus
nonneutr
antibodi
may
play
import
role
antivir
process
hi
titer
may
complet
correl
protect
influenza
viru
conclus
compar
biochem
immunolog
characterist
vlpswttm
compos
hawttm
similar
vlpstm
assembl
releas
supernat
cell
cultur
medium
present
size
ha
spike
howev
vlpstm
trimer
ha
protein
higher
temperatur
resist
moreov
mice
vaccin
vlpstm
could
produc
higher
level
antibodi
cytokin
provid
better
protect
homolog
heterolog
virus
challeng
result
provid
insight
develop
influenza
univers
vaccin
show
great
advantag
vlp
author
conflict
interest
anim
studi
supervis
institut
anim
care
use
committe
sun
yatsen
univers
iacuc
use
accord
regul
guidelin
committe
